
US REGULATORY AFFAIRS CERTIFICATION (RAC) PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://usrac.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1
Table of Contents 2
Introduction 3
How to Use This Guide 4
Questions 5
Answers 8
Explanations 10
Next Steps 16

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. Cosmetics are defined as articles intended for which of the following purposes?

A. To enhance nutritional value

B. To prevent disease

C. For cleansing, beautifying, or altering appearance

D. To act as a pharmaceutical ingredient

2. What does the 510(k) clearance process primarily demonstrate?

A. Safety effectiveness of Class III devices

B. Significant potential risks of a device

C. Substantial equivalence to a pre-amendment device

D. The need for clinical trials for all devices

3. What does 21 CFR 207 regulate?

A. Drug approval process

B. Registration of producers of drugs and listing of drugs in commercial distribution

C. Device premarket processes

D. Clinical trials management

4. What is the role of the Center for Devices and Radiological Health?

A. Evaluating biologics

B. Ensuring device safety and effectiveness

C. Assessing drug interactions

D. Reviewing clinical trial protocols

5. What is the aim of the 515 Program Initiative?

A. To enhance early-phase trial designs

B. To facilitate reclassification of Class III 510(k)s

C. To streamline NDA approval timelines

D. To encourage generic drug competition

SAMPLE

6. Combination products may include which of the following?

A. A device and a prescription medication
B. Only a drug and a biological product
C. A contact lens and a cosmetic
D. A single type of regulated product

7. 21 CFR parts 300s is related to which category of products?

A. Animal drugs
B. Human drugs
C. Foods
D. Cosmetics

8. What is the purpose of guidance documents published by the FDA?

A. To recruit new manufacturers
B. To provide definitive regulations
C. To offer current interpretations of regulations
D. To approve new drugs

9. What is the primary focus of 21 CFR 1271?

A. Medical Device Approval
B. Human Cells, Tissues and Tissue-Based Products
C. Radiological Health
D. Vaccines and Biologics

10. What does ANDA stand for in the context of drug applications?

A. Application for New Drug Approval
B. Abbreviated New Drug Application
C. Annual New Drug Approval
D. Advanced New Drug Application

SAMPLE

Answers

SAMPLE

1. C
2. C
3. B
4. B
5. B
6. A
7. B
8. C
9. B
10. B

SAMPLE

Explanations

SAMPLE

1. Cosmetics are defined as articles intended for which of the following purposes?

A. To enhance nutritional value

B. To prevent disease

C. For cleansing, beautifying, or altering appearance

D. To act as a pharmaceutical ingredient

The definition of cosmetics is centered around their primary purpose, which is to enhance or alter the appearance of the human body. This includes products that are used for cleansing, beautifying, promoting attractiveness, or altering one's appearance without affecting the body's structure or functions in a medical way. Therefore, the focus on cleansing, beautifying, or altering appearance appropriately encompasses the typical uses of cosmetic products as recognized by regulatory standards. Other options refer to functions that do not align with the primary intent behind cosmetics. For instance, enhancing nutritional value pertains more to food products rather than cosmetics, and preventing disease relates to pharmaceutical products or medical devices, which have a different regulatory framework and purpose. Lastly, acting as a pharmaceutical ingredient falls under the category of drugs, which are not defined as cosmetics. This clear distinction helps reinforce why the correct answer emphasizes appearance and beauty, aligning well with how cosmetics are classified by authorities like the FDA.

2. What does the 510(k) clearance process primarily demonstrate?

A. Safety effectiveness of Class III devices

B. Significant potential risks of a device

C. Substantial equivalence to a pre-amendment device

D. The need for clinical trials for all devices

The 510(k) clearance process is primarily designed to demonstrate that a new device is substantially equivalent to an existing legally marketed device, often referred to as a predicate device. This process allows manufacturers to gain clearance for devices that are deemed to have similar indications for use, technological characteristics, and safety and effectiveness profiles as those already on the market. The concept of substantial equivalence is key in the 510(k) process, as it offers a streamlined pathway for devices that do not require the more extensive and resource-intensive Premarket Approval (PMA) process typically reserved for Class III devices. By showing that a new device is substantially equivalent, manufacturers effectively reassure regulatory bodies and the public of its safety and effectiveness based on the existing data pertaining to the predicate device. In contrast, the other choices pertain to different aspects of regulatory processes or requirements: - The notion of demonstrating safety and effectiveness primarily relates to Class III devices, which usually necessitate a PMA instead of a 510(k). - Significant potential risks of a device aren't the focus of the 510(k) process; instead, it is more about proving similarities to predicate devices. - The assertion that clinical trials are necessary for all devices does not reflect the flexibility inherent in the 510(k)

SAMPLE

3. What does 21 CFR 207 regulate?

A. Drug approval process

B. Registration of producers of drugs and listing of drugs in commercial distribution

C. Device premarket processes

D. Clinical trials management

21 CFR 207 specifically regulates the registration of producers of drugs and the listing of drugs that are in commercial distribution. This section of the Code of Federal Regulations outlines the requirements for establishments involved in the manufacturing, repacking, or relabeling of drugs for human use. It mandates that these entities properly register with the FDA and ensure that their products are listed accurately. The registration process helps the FDA track drug manufacturers and the drugs in circulation, facilitating regulatory oversight, safety monitoring, and enforcement actions when necessary. This regulation is critical for maintaining an up-to-date inventory of medical products available in the market, which supports the FDA's mission to protect public health. The focus on registration and listing rather than other areas, such as the approval process, clinical trials management, or device premarket processes, distinguishes 21 CFR 207's specific regulatory intent and scope.

4. What is the role of the Center for Devices and Radiological Health?

A. Evaluating biologics

B. Ensuring device safety and effectiveness

C. Assessing drug interactions

D. Reviewing clinical trial protocols

The Center for Devices and Radiological Health (CDRH) plays a crucial role in the regulation and oversight of medical devices and radiological products, ensuring their safety and effectiveness before they can be marketed to the public. This center is responsible for evaluating premarket submissions, conducting postmarket surveillance, and monitoring the performance of devices once they are on the market to ensure that they continue to meet safety and effectiveness standards. By focusing on device evaluation, the CDRH ensures that all medical devices, including diagnostic equipment, surgical instruments, and in vitro diagnostic devices, meet rigorous regulatory standards designed to protect public health. This involves reviewing clinical data, conducting risk assessments, and assuring compliance with relevant regulations. In contrast, the other options pertain to areas outside the CDRH's primary focus. Evaluating biologics is handled by the Center for Biologics Evaluation and Research, assessing drug interactions is primarily the responsibility of the Center for Drug Evaluation and Research, and reviewing clinical trial protocols typically falls under the purview of Institutional Review Boards and other regulatory bodies rather than the CDRH specifically.

SAMPLE

5. What is the aim of the 515 Program Initiative?

A. To enhance early-phase trial designs

B. To facilitate reclassification of Class III 510(k)s

C. To streamline NDA approval timelines

D. To encourage generic drug competition

The 515 Program Initiative, also known as the Breakthrough Devices Program, primarily aims to accelerate the development and review of innovative devices intended to address unmet medical needs. The initiative provides a pathway for certain medical devices that are designated as breakthrough technologies to benefit from prioritized review and access to the regulatory process. The correct choice reflects the purpose of the program in the context of facilitating the reclassification of devices, particularly Class III devices seeking a 510(k) pathway. By allowing faster and more efficient regulatory pathways, the 515 Program supports technologies that can significantly improve patient care while navigating the complexities associated with traditional market approval processes for devices that may not fit easily into existing classification frameworks. Thus, it helps manufacturers bring novel devices to market more rapidly, which can ultimately provide patients with access to innovative medical solutions that might have previously faced barriers in the traditional regulatory routes. In contrast, the other options address various aspects of regulatory affairs but do not align with the primary goals of the 515 Program.

6. Combination products may include which of the following?

A. A device and a prescription medication

B. Only a drug and a biological product

C. A contact lens and a cosmetic

D. A single type of regulated product

Combination products are defined by their incorporation of two or more regulated components, which can include a drug, device, and/or biological product. The correct answer reflects the understanding that a combination product can consist of a device and a prescription medication, where each component retains its regulatory identity while working together for a specified use. In the case of a device and prescription medication, such as a drug-eluting stent, the device provides a delivery method for the medication, illustrating how these two types can effectively combine to enhance the therapeutic effect. The inclusion of only a drug and a biological product does not encompass the broader range of combination products, as it rules out the potential pairing of devices with drugs or biologicals. The statement regarding a contact lens and a cosmetic also denotes a mix of regulated products, but these do not fall under the traditional regulatory definitions for combination products since they serve distinctly separate functions without a synergistic effect. Lastly, a single type of regulated product contradicts the very nature of combination products, which inherently involves multiple classifications working together. Thus, the most comprehensive understanding of combination products is reflected in the pairing of a device and a prescription medication.

SAMPLE

7. 21 CFR parts 300s is related to which category of products?

A. Animal drugs

B. Human drugs

C. Foods

D. Cosmetics

21 CFR Part 300 specifically addresses regulations concerning human drugs. This part of the Code of Federal Regulations outlines the requirements and standards for the approval, labeling, and manufacturing of human drugs intended for use in the United States. The regulations ensure that human drugs are safe and effective for consumers, detailing procedures for drug approval applications as well as compliance requirements for manufacturers. This part is part of the overall framework that governs various aspects of human pharmaceuticals, including those that require FDA approval before they can be marketed. In contrast, other categories such as animal drugs, foods, and cosmetics are governed by different parts of the CFR, which are tailored specifically to the safety and efficacy concerns relevant to those products. This distinction is crucial for regulatory professionals to understand, as it influences the product development and approval processes within each category.

8. What is the purpose of guidance documents published by the FDA?

A. To recruit new manufacturers

B. To provide definitive regulations

C. To offer current interpretations of regulations

D. To approve new drugs

The purpose of guidance documents published by the FDA primarily revolves around providing current interpretations of regulations. These documents serve as a means for the FDA to communicate its recommendations, approaches, and expectations regarding compliance with regulatory requirements. They address specific aspects of regulatory processes, assisting stakeholders such as manufacturers, researchers, and healthcare providers in understanding how to comply with the laws and regulations governing their activities. Guidance documents are not legally binding but represent the FDA's current thinking on a particular topic, making them valuable resources for those in the industry seeking to ensure they are meeting regulatory expectations. By clarifying the agency's stance on various issues, these documents help reduce uncertainty and risks associated with regulatory submissions and product development. While options like recruiting manufacturers, providing definitive regulations, or approving new drugs are important aspects of the FDA's broader mission, they do not accurately reflect the specific intent and function of guidance documents. Instead, the focus of these documents is to interpret existing regulations and provide clarity, ensuring stakeholders can navigate the regulatory landscape effectively.

SAMPLE

9. What is the primary focus of 21 CFR 1271?

A. Medical Device Approval

B. Human Cells, Tissues and Tissue-Based Products

C. Radiological Health

D. Vaccines and Biologics

The primary focus of 21 CFR 1271 is on the regulation of human cells, tissues, and tissue-based products. This regulation establishes the standards for the manufacturing, processing, and distribution of these biological materials to ensure their safety, efficacy, and quality. It addresses various aspects such as donor eligibility, quality control measures, and labeling requirements, with specific guidelines to prevent the transmission of infectious diseases and to ensure that the products meet the necessary regulatory standards before they are used in medical procedures. This regulation plays a critical role in managing the risks associated with human cell and tissue transplants, as well as promoting public health and safety. Understanding the provisions outlined in 21 CFR 1271 is essential for professionals involved in regulatory affairs, tissue banking, and other related fields. The other choices focus on different areas of regulation and do not pertain specifically to the regulation of human cells and tissues.

10. What does ANDA stand for in the context of drug applications?

A. Application for New Drug Approval

B. Abbreviated New Drug Application

C. Annual New Drug Approval

D. Advanced New Drug Application

The term ANDA stands for Abbreviated New Drug Application. This type of application is essential in the drug approval process for generic medications. An ANDA is submitted to the FDA to obtain approval for a new generic version of an already approved brand-name drug. The significance of the ANDA lies in its streamlined process, allowing manufacturers to demonstrate that their generic product is bioequivalent to the reference listed drug, without the need to conduct large-scale clinical trials again. This regulatory pathway helps promote market competition and can lead to lower drug prices for consumers. In contrast, the other choices reflect different concepts in drug application processes. Application for New Drug Approval refers to the full application required for new, innovative drugs that have not previously been approved. Annual New Drug Approval is not a recognized term in the regulatory framework. Advanced New Drug Application does not exist as a specific term for the regulatory process. The focus of the ANDA process specifically on generics is critical for efficient drug market access and public health.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://usrac.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE